Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donitriptan
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Donitriptan** is a potent, selective, small molecule agonist for the serotonin 5-HT1B and 5-HT1D receptors, previously investigated as an anti-migraine agent. It also displays some agonist activity at the 5-HT2A receptor. Donitriptan belongs to the tryptamine (triptan) drug class, is a derivative of 5-methoxytryptamine, and is chemically related to compounds such as DMT and 5-MeO-DMT. It was originally developed by bioMérieux-Pierre Fabre and reached phase II clinical trials for the treatment of migraine, but development was discontinued and it was never marketed[1][2][3][7].
- Other names
- donitriptan mesylate4-[4-[2-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]piperazin-1-yl]benzonitrileMigraine therapy Pierre Fabre5-HT1D agonist Pierre FabredonitriptanumDonitriptan [INN]DONITRIPTAN [WHO-DD]UNII-70968BVH2JUNII70968BVH2JUNII 70968BVH2J170912-52-470968BVH2JDTXSID20168974DTXSID-20168974DTXSID 20168974DTXCID2091465DTXCID-2091465DTXCID 20914651-(((3-(2-Aminoethyl)indol-5-yl)oxy)acetyl)-4-(p-cyanophenyl)piperazine
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on donitriptan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donitriptan.